TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP) today announced the signing of an agreement providing Aytu BioScience, Inc. (OTCMKTS:AYTU) with the exclusive rights to market NATESTO® in the United States, following the return of the product to Acerus in June of this year. NATESTO® is the first and only FDA-approved testosterone nasal gel indicated for replacement therapy in adult males diagnosed with hypogonadism. Under the terms of the agreement, Acerus will receive a n
![]()
↧